Alterity Therapeutics Limited (ATHE) Fair Value & Analysis
Healthcare · US · Market cap $93.2M
Alterity Therapeutics Limited
ATHE · US
Fair value as of: Jul 14, 2026
From 1 valuation models · updated today
Share price +27.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.92 – $6.55 · fair‑value band $1.34 – $2.54 · the $5.38 price screens above the $2.03 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Alterity Therapeutics Limited (ATHE) currently trades at $5.38, while our model-based Fair Value estimate is $2.03 — implying the stock looks roughly 62.2% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $6.6M. Revenue grew 74.6% year over year. It earns a return on equity of -47.0%. The balance sheet holds a net cash position of $33.0M. Fundamentals as of Jul 14, 2026
Our scenario range runs from $1.34 (bear case) to $2.54 (bull case); at $5.38, the current price sits above that range. The share trades about 23% below its 52-week high and 102% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -62%, ATHE screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Alterity Therapeutics Limited reported revenue of $5.4M in FY2025 versus $4.3M in FY2021, a compound +5.8%/yr. Reported net income was −$12.1M in FY2025.
Is ATHE fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Alterity Therapeutics Limited (ATHE) undervalued?
What is the fair value of ATHE?
What is the quality score of ATHE?
What is the revenue of Alterity Therapeutics Limited (ATHE)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Alterity Therapeutics Limited analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.